Form 4: NeuroOne Medical Technologies Director Jeffrey Mathiesen Granted 50,000 Stock Options

NeuroOne Medical Technologies Corp. Director Jeffrey S. Mathiesen was granted 50,000 stock options with an exercise price of $0.662, vesting over one year, as disclosed in a recent SEC Form 4 filing.

Summary

• Jeffrey S. Mathiesen, a Director of NeuroOne Medical Technologies Corp. (NMTC), was granted 50,000 options to purchase common stock.
• The options have an exercise price of $0.662 per share.
• The transaction date for the grant was June 23, 2025.
• The options will vest in 12 equal monthly installments over a one-year period, with vesting occurring at the end of each month.
• The options have an expiration date of June 23, 2035.
• Following this transaction, Mr. Mathiesen beneficially owns 50,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The granting of stock options to a director is a routine compensation event, generally viewed as positive for aligning management incentives with shareholder interests, without indicating any immediate operational or financial distress.

Positives

• The grant of 50,000 stock options to Director Jeffrey S. Mathiesen aligns his interests with those of shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule over one year encourages long-term commitment and retention of the director.

Future Outlook

The vesting schedule of the options over a one-year period indicates a future commitment and retention strategy for the director, with the full benefit realized upon complete vesting.

Industry Context

The granting of stock options is a common and standard practice in the medical technology industry, as well as across most publicly traded sectors, to compensate directors and executives and align their incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of compensation packages across publicly traded companies, including those in the medical technology sector.
• While specific grant sizes and exercise prices vary by company size, performance, and individual role, the mechanism itself is a widely accepted practice for aligning director interests with long-term company performance.
• No specific comparable companies or projects are detailed in this filing.

Related Party Transactions

• The grant of stock options to Jeffrey S. Mathiesen, a Director, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with long-term shareholder value.
• Director (Jeffrey S. Mathiesen): Receives equity-based compensation, incentivizing performance.

Next Steps

• The options will vest in 12 equal monthly installments over the next year, starting from June 23, 2025.

Key Dates

Recommendation

Keywords

NeuroOne Medical Technologies, NMTC, stock options, director compensation, beneficial ownership, SEC Form 4, equity grant, executive compensation, medical technology